

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 July 2022 (28.07.2022)



(10) International Publication Number
WO 2022/159529 A1

(51) International Patent Classification:

A61K 9/48 (2006.01) A61K 9/52 (2006.01)
A61K 9/00 (2006.01)

(21) International Application Number:

PCT/US2022/013027

(22) International Filing Date:

19 January 2022 (19.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/139,299 19 January 2021 (19.01.2021) US
63/174,497 13 April 2021 (13.04.2021) US

(71) Applicant: **LYNDRA THERAPEUTICS, INC.** [US/US];
65 Grove Street, Suite 301, Watertown, Massachusetts
02472 (US).

(72) Inventors: **KANASTY, Rosemary**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **GRANT, Tyler**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **ALTREUTER, David**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **WEIGHT, Alisha**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **MOORTHY, Saumya**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **SCHWARZ, Marlene**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **JING, Jie**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **DUFOUR, David C.**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **RYDE, Erik Robert Waldemar**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **BHISE, Nupura**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **SIMSES, Craig**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **PEEKE, Erick**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **LAI, Erica**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **TAI, Tammy**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **MONTEZCO, Juan Jaramillo**; c/o Lyndra Therapeutics,

Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **ANNESE, Luigi**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **HERZBERG, Nufar**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **HICKEY, Magali**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US). **VILLANUEVA, Dinara**; c/o Lyndra Therapeutics, Inc., 65 Grove Street, Suite 301, Watertown, Massachusetts 02472 (US).

(74) Agent: **CERPA, Robert K.** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: GASTRIC RESIDENCE SYSTEMS FOR ADMINISTRATION OF RISPERIDONE

(57) Abstract: Gastric residence systems for administration of risperidone are disclosed. Features which enhance gastric retention during the desired residence time and which allow for more precise control over residence time are disclosed, including circumferential filaments connecting the arms of a stellate gastric residence system; improved time-dependent and enteric disintegrating matrices (linkers); and release rate-modulating polymer coatings which are resistant to change in release rate properties during heat-assisted assembly or thermal cycling. Combinations of these features are also disclosed.

WO 2022/159529 A1